Solid Biosciences SLDB
NASDAQ SLDB
$7.60 +0.43 (+6.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Solid Biosciences (SLDB) Return on Sales [ROS] (2022 - 2023)

Updated

Solid Biosciences' Return on Sales [ROS] came in at -1857.21% for Q2 2023, down 1445.76 percentage points from -411.44% a year earlier.

Analysis

Solid Biosciences (SLDB) Return on Sales [ROS] (2022 - 2023) Analysis & Trends

For FY2022, Solid Biosciences' Return on Sales [ROS] was -1315.20%, down 784.70 percentage points from FY2021.

  • Going back by year, Return on Sales [ROS] was -530.50% in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Solid Biosciences 1.08 Bn -212.24 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 -1,857.21%
Dec 31, 2022 -1,729.24%
Sep 30, 2022 -1,474.08%
Jun 30, 2022 -411.44%
API Access

Solid Biosciences Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=SLDB&period=max&api_key=YOUR_API_KEY